Andrew has more than three decades of experience in senior international commercial leadership positions within the Pharmaceuticals and Medical Devices sectors. With a specialization in early access pre-approval unlicensed medicines, he holds key responsibilities in leadership, commercial operations and financial performance. Andrew has had a significant contribution to facilitating medicine access throughout his tenure at Idis/Clinigen, Caligor, Inceptua, and is now Director of Early Access Programmes at Sciensus, Rare Diseases.